Relationship between sarcopenia and nonalcoholic fatty liver disease: The Korean Sarcopenic Obesity Study

Ho Cheol Hong, Soon Young Hwang, Hae Yoon Choi, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Dong Seop Choi, Kyung Mook Choi – 31 August 2013 – Previous studies have shown that nonalcoholic fatty liver disease (NAFLD) and sarcopenia may share pathophysiological mechanisms, such as insulin resistance, inflammation, vitamin D deficiency, and decreased physical activity. However, their direct relationship has not been investigated.

Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice

Ling Yang, Yoon Seok Roh, Jingyi Song, Bi Zhang, Cheng Liu, Rohit Loomba, Ekihiro Seki – 30 August 2013 – Transforming growth factor beta (TGF‐β) signaling activates Smad‐ and TGF‐β‐activated kinase 1 (TAK1)‐dependent signaling to regulate cell survival, proliferation, fibrosis, and tumorigenesis. The effects of TGF‐β signaling on metabolic syndrome, including nonalcoholic fatty liver disease, remain elusive. Wild‐type (WT) and hepatocyte‐specific TGF‐β receptor type II‐deficient (Tgfbr2ΔHEP) mice were fed a choline‐deficient amino acid (CDAA)‐defined diet for 22 weeks to induce NASH.

Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice

Ling Yang, Yoon Seok Roh, Jingyi Song, Bi Zhang, Cheng Liu, Rohit Loomba, Ekihiro Seki – 30 August 2013 – Transforming growth factor beta (TGF‐β) signaling activates Smad‐ and TGF‐β‐activated kinase 1 (TAK1)‐dependent signaling to regulate cell survival, proliferation, fibrosis, and tumorigenesis. The effects of TGF‐β signaling on metabolic syndrome, including nonalcoholic fatty liver disease, remain elusive. Wild‐type (WT) and hepatocyte‐specific TGF‐β receptor type II‐deficient (Tgfbr2ΔHEP) mice were fed a choline‐deficient amino acid (CDAA)‐defined diet for 22 weeks to induce NASH.

Hepatic histological findings in suspected drug‐induced liver injury: Systematic evaluation and clinical associations

David E. Kleiner, Naga P. Chalasani, William M. Lee, Robert J. Fontana, Herbert L. Bonkovsky, Paul B. Watkins, Paul H. Hayashi, Timothy J. Davern, Victor Navarro, Rajender Reddy, Jayant A. Talwalkar, Andrew Stolz, Jiezhun Gu, Huiman Barnhart, Jay H. Hoofnagle, for the Drug‐Induced Liver Injury Network (DILIN) – 28 August 2013 – Drug‐induced liver injury (DILI) is considered to be a diagnosis of exclusion. Liver biopsy may contribute to diagnostic accuracy, but the histological features of DILI and their relationship to biochemical parameters and outcomes are not well defined.

Liver‐specific knockout of GRP94 in mice disrupts cell adhesion, activates liver progenitor cells, and accelerates liver tumorigenesis

Wan‐Ting Chen, Chun‐Chih Tseng, Kyle Pfaffenbach, Gary Kanel, Biquan Luo, Bangyan L. Stiles, Amy S. Lee – 28 August 2013 – Liver cancer is one of the most common solid tumors, with poor prognosis and high mortality. Mutation or deletion of the tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is strongly correlated with human liver cancer. Glucose‐regulated protein 94 (GRP94) is a major endoplasmic reticulum (ER) chaperone protein, but its in vivo function is still emerging.

Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor‐controlled lipid homeostasis

Jiesi Xu, Yuanyuan Li, Wei‐Dong Chen, Yang Xu, Liya Yin, Xuemei Ge, Kavita Jadhav, Luciano Adorini, Yanqiao Zhang – 28 August 2013 – Nonalcoholic fatty liver disease (NAFLD) is one of the major health concerns worldwide. Farnesoid X receptor (FXR) is considered a therapeutic target for treatment of NAFLD. However, the mechanism by which activation of FXR lowers hepatic triglyceride (TG) levels remains unknown. Here we investigated the role of hepatic carboxylesterase 1 (CES1) in regulating both normal and FXR‐controlled lipid homeostasis.

Subscribe to